Compound containing maleimide structure
By developing compounds for inhibiting WRN helicase, the problem of difficult to effectively treat cancers with missing DNA mismatch repair function in the prior art is solved, especially cancers with highly unstable microsatellites, and effective treatment of these cancers is achieved. The patient's survival progression period is prolonged.
Patent Information
- Application Number
- CN202411320055.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-20
AI Technical Summary
The prior art is difficult to effectively treat cancers with missing DNA mismatch repair function, especially those with highly unstable microsatellites, such as colorectal cancer, gastric cancer, endometrial cancer and ovarian cancer, and WRN helicase in these cancer cells The effect has not been fully utilized.
A compound or a pharmaceutically acceptable salt thereof has been developed to prepare an inhibitor of WRN helicase, which inhibits the growth and division of cancer cells by inhibiting the function of WRN. The specific compound structure is that R1 and R2 are halogen or Amino, R3 is a hydroxyl compound, used to treat the above-mentioned cancers.
By inhibiting WRN helicase, the survival and proliferation of highly unstable cancer cells of microsatellites is significantly inhibited, providing a new method to treat cancers with high unstable microsatellites or DNA mismatch repair function, prolonging the patient's Survival progress period.
Smart Images

Figure CN119039203A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound containing a maleimide structure, use thereof and a pharmaceutical composition containing the compound. Background Art
[0002] During the progression of cancer, loss of DNA mismatch repair function often occurs, such as in 10%-30% of colorectal cancer, endometrial cancer, ovarian cancer and gastric cancer. Due to the loss of DNA mismatch repair function, the mutation burden of cancer cells becomes higher, and deletions or insertions often occur in the repetitive sequence regions of DNA. This phenomenon is called microsatellite instability. Although progress has been made in the treatment of microsatellite high instability (MSI-H) cancer, and pembrolizumab (PD-1 antibody) as a first-line treatment shows a longer survival progression period than chemotherapy for patients with advanced colorectal cancer with microsatellite high instability / DNA mismatch repair function loss (MSI-H / dMMR), pembrolizumab has been approved for the first-line treatment of MSI-H / dMMR cancer, but there is still a demand for colorectal cancer and other MSI-H indications in clinical practice.
[0003] Through large-scale functional genomics screening of multiple cell lines, including Novartis' analysis of 398 cell lines from the Cancer Cell Line Encyclopedia (CCLE) cell bank (McDonald E R et al., Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell 170 (3): 577-592 (2017)), it was found that WRN (Werner syndrome protein) is essential for the survival of cell lines with microsatellite high instability (MSI-H) due to loss of DNA mismatch function (Behan, FM et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511-516 (2019); Chan, EM et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568,551-556(2019); Kategaya,L.,Perumal,SK,Hager,JH&Belmont,LDWerner syndrome helicase is required for the survival ofcancer cells with microsatellite instability.iScience 13,488-497(2019); Lieb,S.etal.Werner syndrome helicase is a selective vulnerability ofmicrosatellite instability-high tumor cells.Elife 8,e43333(2019)). WRN and MSI-H have a synthetic lethal relationship. In cancer cells with DNA mismatch repair function deficiency, the loss of WRN inhibits cell proliferation, activates multiple DNA damage biomarkers, and induces cell division arrest and apoptosis. However, for cancer cells with intact DNA mismatch repair function, the loss of WRN does not lead to such results.These findings indicate that WRN provides the DNA repair and maintenance functions that MSI-H cancer cells rely on for survival. Recently, the mechanism by which MSI-H cells rely on WRN has been studied: the two-nucleotide TA repeat sequence is unstable only in MSI-H cells, and can be amplified on a large scale, thereby forming an atypical DNA secondary structure that requires WRN to unwind (Van Wietmarschen, N. et al. Repeat expansions confer WRN dependency in microsatellite-unstable cancers. Nature 586, 292-298, 200.). In the absence of WRN (or the unwinding function of WRN is inhibited), the amplified TA repeat sequence in MSI-H cells will be cut by nucleases, resulting in chromosome breakage. Therefore, for cancer cells with DNA mismatch function loss, inhibiting the helicase function of WRN is an attractive therapeutic strategy.
[0004] New management and treatment approaches are still needed for cancer, especially for cancers with microsatellite instability-high (MSI-H) or deficient DNA mismatch repair (dMMR), including colorectal, gastric, endometrial, or ovarian cancers. Summary of the invention
[0005] The present invention provides a compound of the following formula (I) or a pharmaceutically acceptable salt thereof:
[0006]
[0007] Wherein, R1 and R2 are each independently halogen or NH2; R3 is hydroxyl or
[0008] In a more preferred embodiment, R1 is halogen; R2 is halogen or NH2.
[0009] In a more preferred embodiment, R1 is chlorine; R2 is chlorine or NH2.
[0010] The compound or pharmaceutically acceptable salt thereof described in the present invention may be any of the following compounds:
[0011]
[0012] The present invention also provides the use of the compound shown above or a pharmaceutically acceptable salt thereof in the preparation of a WRN inhibitor, including the use in the treatment of colorectal cancer, gastric cancer, endometrial cancer or ovarian cancer.
[0013] The present invention also provides a pharmaceutical composition, which comprises the compound shown above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0014] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. DETAILED DESCRIPTION
[0015] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0016] Example 1 EVO32627
[0017]
[0018] 4-(Aminomethyl)cyclohexanecarboxylic acid (500.00 mg, 3.18 mmol) and 2,3-dichloromaleic anhydride (535.00 mg, 3.18 mmol) were dissolved in acetic acid solution (8 mL) and stirred at 120 degrees Celsius for 1.5 hours. After cooling to room temperature, the mixture was directly separated and purified by silica gel column chromatography to obtain white solid EVO32627 (430.00 mg, yield 44%). LCMS (ESI) m / z = 304.0 [MH] - . 1 H NMR (400MHz, DMSO-d6): δ12.0(s,1H),3.32(s,2H),2.12(s,1H),1.87(d,J=12.9Hz,2 H), 1.71 (d, J = 12.7Hz, 2H), 1.54 (s, 1H), 1.23 (q, J = 12.3, 2H), 0.96 (t, J = 12.6Hz, 2H).
[0019] Example 2 EVO32657
[0020]
[0021] Step 1:
[0022] At room temperature, under nitrogen protection, 4-((3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxylic acid (100.00 mg, 0.33 mmol) was dissolved in N-methylpyrrolidone (2 mL), 3-aminobenzenesulfonic acid (63.00 mg, 0.36 mmol) was added, and thionyl chloride (0.03 mL, 0.40 mmol) was added dropwise. The reaction was stirred at 40 degrees Celsius for 16 hours. After cooling to room temperature, water (0.2 mL) was added to quench the reaction, and light yellow solid EVO32657 (26.30 mg, 17.3%) was obtained by direct separation and purification by reverse phase column chromatography (water / acetonitrile = 5% to 95%). LCMS (ESI) m / z = 461.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6): δ9.85(s,1H),7.79(s,1H),7.65-7.61(m,1H),7.24-7.18(m,2H),3.35-3.30( m,2H),2.28-2.24(m,1H),1.86-1.73(m,4H),1.56-1.54(m,1H),1.40-1.29(m,2H),1.02-0.92(m,2H).
[0023] Example 3 EVO32654
[0024]
[0025] Step 1:
[0026] EVO32627 (200 mg, 0.66 mmol) and ammonia (2 ml) were dissolved in ethanol (4 ml), reacted at 70 degrees Celsius for 2 hours, cooled to room temperature, and directly separated and purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to obtain yellow solid EVO32654 (30 mg, 16%). LCMS (ESI) m / z = 287.1 [M+H] + .
[0027] 1 H NMR (DMSO-d6, 400MHz): δ12.03(s,1H),7.64(s,2H),3.22–3.17(m,2H),2.11–2.05(m,1H) ,1.89–1.82(m,2H),1.64–1.57(m,2H),1.50(s,1H),1.25–1.14(m,2H),0.97–0.84(m,2H).
[0028] Biological Effect Examples
[0029] Protein expression and purification of WRN truncation
[0030] Construction of expression vector:
[0031] 1. Synthesize the cDNA sequence encoding WRN (N517-Q1093) (Genscript Biotech
[0032] Corporation) with an 8xHis tag-Strep-TEV cleavage site at the N-terminus.
[0033] into pFastBac1 vector (YouBio, catalog number), with insertion sites at BamHI and EcoRI,
[0034] to pFastBac1-8His-Strep-TEV-WRN(N517-Q1093) recombinant plasmid;
[0035] 2. Take 50 μL DH10Bac competent cells (biomed, #BC112-01) and slowly melt them on ice, add 1 μL pFastBac1-8His-Strep-TEV-WRN (N517-Q1093) recombinant plasmid, incubate on ice for 30 minutes, then incubate in 42°C water bath for 45 seconds, and incubate on ice for 2 minutes;
[0036] 3. Add 450 μL SOC medium (2% Tryptone (OXOID, #LP0042), 0.5% Yeast Extract (OXIOD, #LP0021), 0.58% NaCl (Hushi, #10019360), 0.019% KCl (Hushi, 1002792168398), 0.203% MgCl2·6H2O (Hushi, 10012828), 0.246% MgSO4·7H2O (Hushi, 10013016), 0.36% Glucose (Biodee, #DE0149-500g)), place in a horizontal shaker at 220 rpm and 37°C for 4 h;
[0037] 4. Dilute the cell suspension 10-fold with SOC medium, and then take 50uL to coat agarose plate (take 1% Tryptone, 0.5% Yeast Extract, 1% NaCl, 1.5% Agar (BioFroxx,
[0038] #8211GR500), 50μg / mL Kanamycin (Solarbio, #K8020-5g), 7μg / mL Gentamycin (Solarbio, G8170-1g), 10μg / mL Tetracycline (Solarbio, #T8180-5g), 40μg / mL X-gal (Solarbio, #8050-1g) and 40μg / ml IPTG (lnalco, #1758-1400), 37°C, protected from light for 48h;
[0039] 5. Pick two monoclonal colonies and place them in 5 mL SOC medium respectively, and culture them at 37°C and 250 rpm overnight;
[0040] Extraction of recombinant Bacmid:
[0041] 1. Take 1.5 mL of colony culture medium into an EP tube (Axygen, #MCT-200-CS) and centrifuge at 13300 rpm for 1 minute;
[0042] 2. Remove the supernatant and extract the recombinant Bacmid using a plasmid extraction kit (Qiagen #DP103-03).
[0043] Experimental steps: Refer to the kit instructions. Transfer the supernatant after centrifugation to a new tube and add 750 μL
[0044] isopropanol (Greagent, #G75885B), gently mix several times, and place on ice for 10 minutes;
[0046] 3.13, centrifuge at 300 rpm for 15 minutes;
[0047] 4. Remove the supernatant, add 500 μL 70% ethanol (Greagent, Product No. 1101143), and place the EP tube
[0048] Repeatedly flip 8 times, wash the precipitate, and centrifuge at 13,300 rpm for 5 minutes;
[0049] 5. Remove the supernatant and add 500 μL of autoclaved 70% ethanol in a sterile environment of a clean bench;
[0050] 6. Repeat steps 8 and 9;
[0051] 7. Remove excess supernatant as much as possible and centrifuge at 13,300 rpm for 2 minutes;
[0052] 8. Air-dry the precipitate for 5 minutes and dissolve it in 40 μL of autoclaved TE buffer;
[0053] 9. Determine the concentration of recombinant Bacmid using Nanodrop;
[0054] Insect cell transfection:
[0055] 1. Dilute Sf9 cells (Gibco,
[0056] #11496015) to 1×10 6 cells / mL, take 3mL into a 25mL culture flask;
[0057] 2. Take 15 μg of recombinant Bacmid and add 100 μL Grace's Insect Medium (Gibco,
[0058] #11605094), and then add 7 μL X-treme transfection reagent (Roche
[0059] #6366236001), incubate at room temperature for 15-20 minutes
[0060] 3. The incubation product was transferred to a culture flask containing Sf9 cell solution and cultured at 27°C and 100 rpm for 4 days;
[0061] Collect P0 virus:
[0062] 4. Observe the cell status 4 days after transfection and prepare to collect the virus;
[0063] 5. First add serum (final concentration 2%, Sijiqing #11011-8611), centrifuge at 3200 rpm for 5 minutes at 4°C;
[0064] 6. Collect the supernatant and store at 4°C, which is recorded as P0 virus;
[0065] P1 virus preparation:
[0066] 7. Take 1 mL of P0 virus and add 50 mL of Sf9 cell culture medium (cell density 1.5-1.8×10 6
[0067] cells / mL), cultured at 27°C and 100 rpm for 3 days;
[0068] 8. After 3 days of culture, detect the cell status and prepare to collect the cells;
[0069] 9. Add serum (final concentration 2%) and centrifuge at 3500 rpm for 5 minutes at 4°C;
[0070] 10. Collect the supernatant and store at 4°C, which is recorded as P1 virus;
[0071] P2 virus preparation:
[0072] 11. Take 4 mL of P1 virus and add it to 200 mL of Sf9 cell culture medium (cell density 1.5-1.8×
[0073] 10 6 cells / mL), cultured at 27°C and 100 rpm for 3 days;
[0074] 12. After 3 days of culture, detect the cell status and prepare to collect the cells;
[0075] 13. Add serum (final concentration 2%) and centrifuge at 3500 rpm for 5 minutes at 4°C;
[0076] 14. Collect the supernatant and store it at 4°C, which is recorded as P2 virus.
[0077] Protein expression and purification:
[0078] 15.6 bottles of 800mL Sf9 cell culture medium (2×10 6 cells / mL), 12.8 mL of P2 virus was added to each of the 100 cells / mL cells and cultured at 27°C and 100 rpm for 48 h;
[0079] Centrifuge at 8000 rpm for 10 min at 16.4°C to collect cells;
[0080] 17. Resuspend the cells in 800 mL of cell lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 1 mM PMSF, 5 mM MgCl2) and add one tablet of cOmplete™ protein inhibitor (Roche #11697498001);
[0081] 18. High-pressure cell disruption (Nanjing Natong Electromechanical Manufacturing, model NT-H3, working pressure 650 bar), repeated disruption 4 times, followed by centrifugation at 4°C 16000 rpm for 60 minutes, and the supernatant was collected for affinity chromatography:
[0082] 1) Over Affinity column (5 mL, IBA lifesciences #2-5027-001), eluted with a buffer of 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 1 mM PMSF, 75 mM Biotin;
[0083] 2) Add 6His-GST-Thrombin-TEV protease to the eluted product and digest it overnight at 4°C;
[0084] 3) The digested product was passed through HiTrap Heparin HP (5 mL, GE Healthcare #17-0406-01) for ion exchange;
[0085] 4) Remove residual protease by GST column;
[0086] 5) Purification was performed by size exclusion chromatography using HiLoad 16 / 600 Superdex 200 pg (GE Healthcare #28-9893-35) at a flow rate of 1 mL / min;
[0087] 19. SDS-PAGE was used to detect protein purity. The protein purity should be greater than 99%. The protein was frozen at -80°C for subsequent enzyme activity testing.
[0088] Inhibition assay of compounds on ATPase activity of WRN truncated forms
[0089] ADP-Glo TM The kinase kit (Promega #V9101) is a chemiluminescent ADP detection method with the advantages of strong versatility, good uniformity and high-throughput screening. It can be used to detect the activity of ADP-generating enzymes (such as ATPase). The test is carried out in two steps: first, after the kinase reaction, ADP-Glo TM The reagent terminates the kinase reaction and consumes the remaining ATP; then the kinase detection reagent is added to convert ADP into ATP, and the newly synthesized ATP is measured by the luciferase / luciferin reaction, and the chemiluminescent signal is detected by the photometer. The light signal is positively correlated with the content of ADP, so the inhibition of WRNATPase activity by compounds of different concentrations can be measured, thereby fitting the concentration-effect curve and calculating the IC50 of the compound. The specific steps are as follows:
[0090] The buffer used in this experiment was 25 mM HEPES (Gibco #15630-080), 5 mM NaCl (Sigma #59222C-100ML), 0.01% F-127 (Sigma #P2443), 1 mM MgCl2 (Sigma #M1028-100ML), and 1 mM TCEP (Sigma #646547).
[0091] 1. Dissolve the compound in DMSO to prepare a 10mM stock solution, and dilute the compound to be tested in a 3-fold gradient, with a total of 8 concentration points. Take 3uL of compound solution and add it to No. 1 384-well plate (PerkinElmer #6008280). Add 3uL 5% DMSO to the minimum inhibition control well (High Control) and the enzyme-free control well (Low Control) respectively;
[0092] 2. Add 6uL of 5nM WRN truncation solution to each well and incubate with the compound for 10 minutes at room temperature.
[0093] 3. Add 6uL of a mixed solution of ATP and DNA duplex fork (2.5mM ATP, 25nM DNA) to each well to prepare a 15uL reaction system and react at room temperature for 60 minutes;
[0094] 4. Take 5uL of the reaction system into each well and add 5uL of ADP Glo reagent stop solution (ADP-Glo TM Kinase kit) in No. 2 384-well plate, incubate at room temperature for 50 minutes, and terminate the reaction;
[0095] 5. Take 5uL ADP (ADP-Glo TM Kinase kit) was added with 5uL ADP Glo reagent (ADP-Glo TM Kinase kit) wells (standard control wells);
[0096] 6. Add 10uL Kinase Detection Reagent (ADP-Glo TM Kinase kit) and incubated at room temperature for 40 minutes. The optical signal value was read using SpectraMaxi3x;
[0097] 7. Data analysis: Compound well inhibition rate (Inhibition%) = (avg High Control-Cpd well) / (avg High Control-Low Control)*100%. GraphPad Prism 9.0 software was used to draw the concentration effect curve and calculate IC using the four-parameter fitting equation. 50 value.
[0098] Detection of the inhibition of DNA unwinding activity of WRN truncations by compounds
[0099] Experimental principle: After annealing, two incompletely paired single-stranded DNA fragments with a quencher and a fluorescent group can form a DNA duplex fork structure. WRN can unwind the DNA duplex fork into single-stranded DNA, thereby detecting the level of single-stranded DNA through fluorescent signals and evaluating the helicase activity of WRN. The specific experimental steps are as follows:
[0100] The buffer used in this experiment is consistent with the buffer formula of the ATPase activity experiment.
[0101] 1. Synthesize single-stranded DNA fragment (quenched single-stranded DNA of SEQ ID NO: 1:
[0102] TTTTTTTTTTTTTTTTTTCGTACCCGATGTGTTCGTTC, fluorescent single-stranded DNA of SEQ ID NO: 2: GAACGAACACATCGGGTACGTTTTTTTT, synthesized by Shanghai Sangon Biotechnology Co., Ltd., purified by HPLC), enzyme-free water (Invitrogen
[0103] #10977015) Dissolve the primer to 100uM;
[0104] 2. Dilute the single-stranded DNA fragment to 20uM with 500mM NaCl solution (final NaCl concentration 50
[0105] mM), and make up the volume with enzyme-free water. Take equal amounts of single-stranded DNA fragments and mix them (10uM) and place them in
[0106] In the PCR instrument (BIORAD#C1000 Touch), the program was set as follows: 95°C for 5 minutes, 25°C for 1
[0107] minutes (Ramp: 0.1℃ / s), 4℃30 minutes, single-stranded DNA annealing, DNA
[0108] duplex fork;
[0109] 3. Take 20uL 30nM fluorescent single-stranded DNA fragment and 20uL 30nM DNA duplex fork into 384-well plate (Corning#4514) respectively, and detect the fluorescence signal with microplate reader: excitation wavelength 520nm emission wavelength 590nm. Calculate the annealing efficiency according to the corresponding fluorescence signals: (DNA duplex fork /
[0110] Single-stranded DNA) × 100%, annealing efficiency needs to be > 90%;
[0111] 4. The compound was dissolved in DMSO to prepare a 10 mM stock solution, and the compound to be tested was diluted 3-fold in a gradient, with a total of 10 dilution points (7.5× compound detection concentration, 7.5% DMSO);
[0112] 5. Take 2uL of compound solution and add it to a 384-well plate. Add 2uL of 7.5% DMSO to the minimum inhibition control well (High Control) and the no enzyme control well (Low Control) respectively;
[0113] 6. Add 5uL of 6nM WRN truncation solution to each well, centrifuge at 1000rmp for 1 minute, and incubate at room temperature for 30 minutes;
[0114] 7. Add 8uL of a mixture of DNA duplex fork and ATP (18.75nM DNA, 5.63mM ATP) to each well, centrifuge at 1000rmp for 1 minute, and react at room temperature for 20 minutes;
[0115] 8. Add 4uL 1.625% SDS solution (Sigma #75746-250G) to each well to terminate the reaction;
[0116] 9. Use a fluorescence microplate reader (MD SpectraMax i3x) to read the excitation wavelength of 520nm and the emission wavelength of 590
[0117] Fluorescence signal intensity in nm;
[0118] 10. Data analysis: Compound well inhibition rate (Inhibition%) = (avg High Control-Cpdwell) /
[0119] (avg High Control-Low Control)*100%, GraphPad Prism 9.0 software was used to draw the concentration effect curve and calculate the IC using the four-parameter fitting equation 50 The results are as follows:
[0120]
[0121]
[0122] Where A represents IC 50 ≤100nM; B means 100nM<IC 50 ≤1000nM; C means 1000nM<IC 50 ≤10000nM; “-” means not tested.
Claims
1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: in, R1 and R2 are each independently halogen or NH2; R3 is hydroxyl or 2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is halogen; R2 is halogen or NH2.
3. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein R1 is chlorine; R2 is chlorine or NH2.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is any of the following compounds:
5. A pharmaceutical composition, characterized in that It comprises the compound according to any one of claims 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
6. Use of the compound or pharmaceutically acceptable salt or composition according to any one of claims 1 to 5 in the preparation of a WRN inhibitor.
7. The use according to claim 6 is for treating colorectal cancer, gastric cancer, endometrial cancer or ovarian cancer.
Citation Information
Patent Citations
Maleimide group-modified angiogenesis inhibitor HM-1 and application thereof
CN109503700A
Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
US20030032625A1
Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
WO2002078679A2
Cited By
Pharmaceutical combinations and uses thereof
WO2025215527A2
